{"hands_on_practices": [{"introduction": "The hallmark of a psoriatic plaque is its thick, adherent scale, a direct consequence of epidermal hyperproliferation. This exercise models the keratinocyte life cycle as a steady-flow system to provide a quantitative understanding of this process. By calculating the change in epidermal turnover time based on an increased mitotic rate, you will connect a fundamental pathophysiological abnormality to its macroscopic clinical manifestation, reinforcing why scale forms so rapidly in psoriatic skin [@problem_id:4488452].", "problem": "In human epidermal homeostasis, keratinocytes produced by basal layer mitoses enter a differentiating pipeline and ultimately desquamate from the surface. Consider a stationary, steady-state epidermal system in which the number of keratinocytes within the viable-to-corneocyte differentiating compartment is temporally constant. Normal epidermal turnover time is approximately $28$ days, meaning a typical keratinocyte requires $28$ days from its basal exit into differentiation to surface shedding under normal conditions. In a psoriatic plaque, the mitotic rate of basal keratinocytes increases by a factor of $3$ compared to normal, with the fraction of mitoses yielding differentiating progeny unchanged. Assume an early time frame in which the differentiating compartment size has not yet remodeled.\n\nStarting from conservation of cell number in a steady-flow system, and without invoking any pre-stated shortcut formulas, derive how the mean turnover time relates to the production flux and the size of the differentiating pool, then compute the theoretical new turnover time under the above assumptions. Round your final numerical answer to three significant figures and express it in days. Briefly explain, based on your derivation, the implications of this shortened turnover time for scale formation in psoriatic plaques when the desquamation machinery cannot proportionally increase its throughput.\n\nOnly the numerical turnover time is to be provided as the final answer.", "solution": "We model the epidermis as a steady-flow system of keratinocytes. Let $N$ denote the mean number of cells in the differentiating compartment spanning from basal exit to surface shedding. Let $J$ denote the steady inflow of differentiating cells per unit time, which at steady state equals the outflow by desquamation. Let $T$ denote the mean residence (turnover) time from entry into the differentiating compartment to exit at the surface.\n\nWe begin from conservation of cell number in steady state. Over an interval of duration $\\Delta t$ that is long compared to microscopic events but short compared to system remodeling, the number of cells entering the compartment is $J \\Delta t$, and the number exiting is also $J \\Delta t$. The average number of cells present in the compartment is the time average of occupancy, which for a renewal process equals the inflow rate multiplied by the mean sojourn time. This statement can be derived by considering the age distribution of cells. Let $a \\in [0,\\infty)$ denote the age (time since entry into the differentiating compartment). Let $p(a)$ denote the probability density of exit at age $a$, with $\\int_{0}^{\\infty} p(a) \\,\\mathrm{d}a = 1$ and mean $\\int_{0}^{\\infty} a \\, p(a) \\,\\mathrm{d}a = T$. In steady state with constant inflow $J$, the density of cells with ages in $[a,a+\\mathrm{d}a]$ equals $J$ times the probability that a cell survives to age $a$ times $\\mathrm{d}a$, namely $J S(a)\\,\\mathrm{d}a$, where $S(a) = 1 - \\int_{0}^{a} p(u)\\,\\mathrm{d}u$ is the survival function. The total number in the compartment is then\n$$\nN \\;=\\; \\int_{0}^{\\infty} J S(a)\\,\\mathrm{d}a.\n$$\nIntegrating by parts using $S(a) = \\int_{a}^{\\infty} p(u)\\,\\mathrm{d}u$ yields\n$$\nN \\;=\\; J \\int_{0}^{\\infty} \\left( \\int_{a}^{\\infty} p(u)\\,\\mathrm{d}u \\right) \\mathrm{d}a \\;=\\; J \\int_{0}^{\\infty} u \\, p(u)\\,\\mathrm{d}u \\;=\\; J T.\n$$\nThus, at steady state,\n$$\nN \\;=\\; J T.\n$$\n\nLet the normal state be denoted by subscript $0$: $N_{0}$, $J_{0}$, $T_{0}$. We are given $T_{0} = 28$ days. In the psoriatic state immediately after the mitotic rate increase and before compartment remodeling, we assume $N$ has not changed from its normal value, i.e., $N_{1} = N_{0}$. The basal mitotic rate increases by a factor of $3$, and the fraction of mitoses producing differentiating progeny is unchanged, so the flux into the differentiating compartment scales by the same factor, giving $J_{1} = 3 J_{0}$.\n\nApplying $N = J T$ to both states:\n$$\nN_{0} = J_{0} T_{0}, \\quad N_{1} = J_{1} T_{1}.\n$$\nWith $N_{1} = N_{0}$ and $J_{1} = 3 J_{0}$, we have\n$$\nJ_{0} T_{0} \\;=\\; 3 J_{0} T_{1} \\;\\;\\Rightarrow\\;\\; T_{1} \\;=\\; \\frac{T_{0}}{3} \\;=\\; \\frac{28}{3} \\text{ days}.\n$$\nNumerically,\n$$\nT_{1} \\;=\\; 9.333\\ldots \\text{ days}.\n$$\nRounding to three significant figures yields $9.33$ days.\n\nImplications for scale formation: Because $T$ shortens, keratinocytes traverse the differentiation program more rapidly. If the desquamation machinery (for example, corneodesmosome degradation, protease activation, and stratum corneum lipid processing) cannot increase its throughput in proportion to the $3$-fold higher inflow, then the outflow remains closer to $J_{0}$ while inflow is $3 J_{0}$. The net accumulation rate within the cornified layers becomes approximately $(3 J_{0} - J_{0}) = 2 J_{0}$, leading to progressive thickening of the stratum corneum (hyperkeratosis) and visible scale. Furthermore, the abbreviated residence time $T_{1}$ reduces the time available for complete terminal differentiation, favoring retention of nuclei in the stratum corneum (parakeratosis), a histologic hallmark of psoriatic scale. These consequences emerge directly from the steady-flow relation $N = J T$ and the mismatch between production flux and desquamation capacity.", "answer": "$$\\boxed{9.33}$$", "id": "4488452"}, {"introduction": "Psoriatic disease is a systemic inflammatory condition, and recognizing its articular manifestations is a critical diagnostic skill. The Classification criteria for Psoriatic Arthritis (CASPAR) provide a standardized framework for this purpose. This practice problem challenges you to apply the CASPAR criteria to a detailed clinical vignette, honing your ability to synthesize history, physical exam findings, and laboratory data to accurately classify a patient with inflammatory arthritis in the context of psoriasis [@problem_id:4488408].", "problem": "A patient presents to clinic with joint pain and skin findings. You are asked to apply the Classification criteria for Psoriatic Arthritis (CASPAR) to compute a classification score. Use only established, widely accepted diagnostic facts as the foundation for your reasoning. Do not assume any unstated features. The patient data are as follows:\n\n- The patient has inflammatory articular disease: clinical synovitis in small joints of the hands with morning stiffness lasting longer than $45$ minutes and elevated acute phase reactants; an experienced rheumatologist has confirmed active peripheral inflammatory arthritis.\n- Cutaneous findings: well-demarcated erythematous plaques with micaceous scale on both elbows and knees, consistent with active psoriasis on current examination.\n- Nail findings: fingernails demonstrate onycholysis with distal subungual hyperkeratosis and multiple punctate pits.\n- Serology: rheumatoid factor (RF) by nephelometry is below the laboratory’s negative cutoff (reported as negative).\n- Dactylitis: there is documented prior dactylitis of the left second toe confirmed in a rheumatology note from $1$ year ago; there is no current dactylitis today.\n- Imaging: plain radiographs of the hands show ill-defined juxta-articular new bone formation at the bases of several phalanges (periostitis) without osteophytes typical of osteoarthritis.\n\nUsing the CASPAR framework, compute the total score $S$ for this patient by evaluating the following five domains explicitly listed above: current psoriasis, nail dystrophy, negative rheumatoid factor, dactylitis (current or prior), and radiographic juxta-articular new bone formation. Express the final value of $S$ as an integer. Recall that, for classification, psoriatic arthritis is considered present if and only if $S \\geq 3$ in the setting of inflammatory articular disease. No rounding is required.", "solution": "The problem presented is a valid application of a well-established medical classification system. It is scientifically grounded, well-posed, and objective, as it requires the direct application of the Classification criteria for Psoriatic Arthritis (CASPAR) to a set of clearly defined clinical data. The task is to compute a total score, $S$, based on these criteria.\n\nThe CASPAR framework requires a patient to first meet an entry criterion. The patient must have inflammatory articular disease, which can manifest as peripheral arthritis, axial disease, or enthesitis. The problem states that the patient has \"inflammatory articular disease: clinical synovitis in small joints of the hands with morning stiffness lasting longer than $45$ minutes and elevated acute phase reactants; an experienced rheumatologist has confirmed active peripheral inflammatory arthritis.\" This statement explicitly confirms that the entry criterion is met.\n\nWith the entry criterion satisfied, we proceed to calculate the score $S$ by summing the points from five domains, as per the problem statement. The total score $S$ is the sum of the scores from each domain: $S = S_{\\text{psoriasis}} + S_{\\text{nail}} + S_{\\text{RF}} + S_{\\text{dactylitis}} + S_{\\text{radio}}$.\n\n1.  **Psoriasis ($S_{\\text{psoriasis}}$):** The CASPAR criteria assign $2$ points for current psoriasis, $1$ point for a personal history of psoriasis, or $1$ point for a family history of psoriasis. The patient is described as having \"well-demarcated erythematous plaques with micaceous scale on both elbows and knees, consistent with active psoriasis on current examination.\" This qualifies as current, active psoriasis. Therefore, the score for this domain is $S_{\\text{psoriasis}} = 2$.\n\n2.  **Nail Dystrophy ($S_{\\text{nail}}$):** The criteria award $1$ point for the presence of psoriatic nail dystrophy, which includes onycholysis, pitting, and hyperkeratosis, observed on current examination. The patient's \"fingernails demonstrate onycholysis with distal subungual hyperkeratosis and multiple punctate pits.\" This description unequivocally fulfills the criterion. Thus, the score for this domain is $S_{\\text{nail}} = 1$.\n\n3.  **Negative Rheumatoid Factor ($S_{\\text{RF}}$):** The criteria assign $1$ point for a negative test for rheumatoid factor (RF) using a method other than latex agglutination, with ELISA or nephelometry being preferred. The patient's serology shows \"rheumatoid factor (RF) by nephelometry is below the laboratory’s negative cutoff (reported as negative).\" This meets the requirement for a negative RF by a preferred method. Therefore, the score for this domain is $S_{\\text{RF}} = 1$.\n\n4.  **Dactylitis ($S_{\\text{dactylitis}}$):** The criteria grant $1$ point for either current dactylitis (swelling of an entire digit) or a documented history of dactylitis recorded by a physician. The problem notes \"documented prior dactylitis of the left second toe confirmed in a rheumatology note from $1$ year ago.\" Even though there is no current dactylitis, the recorded history is sufficient to satisfy the criterion. The score for this domain is $S_{\\text{dactylitis}} = 1$.\n\n5.  **Radiographic Evidence ($S_{\\text{radio}}$):** The criteria award $1$ point for radiographic evidence of juxta-articular new bone formation on plain radiographs of the hands or feet, which must be distinct from the osteophytes seen in osteoarthritis. The patient's \"plain radiographs of the hands show ill-defined juxta-articular new bone formation at the bases of several phalanges (periostitis) without osteophytes typical of osteoarthritis.\" This finding is a direct match for the radiographic criterion. Consequently, the score for this domain is $S_{\\text{radio}} = 1$.\n\nTo find the total score $S$, we sum the points from each of the five evaluated domains:\n$$\nS = S_{\\text{psoriasis}} + S_{\\text{nail}} + S_{\\text{RF}} + S_{\\text{dactylitis}} + S_{\\text{radio}}\n$$\nSubstituting the determined values:\n$$\nS = 2 + 1 + 1 + 1 + 1 = 6\n$$\nThe total CASPAR score for this patient is $6$. According to the criteria, a score $S \\geq 3$ is required for a patient with inflammatory articular disease to be classified as having psoriatic arthritis. Since $6 \\geq 3$, this patient meets the classification for psoriatic arthritis. The question, however, only asks for the numerical value of the score $S$.", "answer": "$$\\boxed{6}$$", "id": "4488408"}, {"introduction": "Initiating and managing systemic therapies like methotrexate are cornerstone skills in the treatment of moderate-to-severe psoriatic disease. Safe and effective use extends beyond simple prescribing; it requires careful patient risk stratification, precise dosing, and diligent laboratory monitoring. This exercise simulates a realistic clinical scenario, tasking you with integrating patient-specific risk factors with standard treatment protocols to navigate the complexities of long-term methotrexate management [@problem_id:4488448].", "problem": "A 52-year-old individual with chronic plaque psoriasis and nail disease is initiated on oral methotrexate for systemic control after inadequate response to topical therapy and phototherapy. The patient weighs 70 kg and has the following comorbidities and lifestyle factors: body mass index $32 \\text{ kg/m}^2$, type $2$ diabetes mellitus, nonalcoholic fatty liver disease (NAFLD), and consumption of approximately 14 standard alcoholic drinks per week. Baseline laboratory values show transaminases at the upper limit of normal with preserved synthetic function; renal function is normal. No other hepatotoxic drugs are used.\n\nMethotrexate is started at 15 mg once weekly without a loading dose. The clinic standard folate supplementation protocol is folic acid 1 mg daily except on the day methotrexate is taken. The clinic’s laboratory monitoring protocol specifies obtaining a Complete Blood Count (CBC) and a Comprehensive Metabolic Panel (CMP) at baseline (week $0$), every $2$ weeks through week $12$ inclusive (weeks $2,4,6,8,10,12$), then every $4$ weeks at weeks $16,20,24$, and thereafter every $8$ weeks (weeks $32,40,48,56,64,72,80,88,96,104,\\dots$) while the dose is stable. The clinic uses a cumulative-dose threshold approach to trigger noninvasive hepatic fibrosis assessment: in high-risk patients (defined by features such as obesity, NAFLD, diabetes mellitus, or significant alcohol intake), the threshold is a cumulative methotrexate dose of 1.5 g; in low-risk patients, it is 3.5 g.\n\nStarting from fundamental pharmacology and risk stratification principles for methotrexate in psoriasis, and using only the information given:\n- Compute the weekly methotrexate dose per kilogram.\n- Determine the weekly folic acid intake from the specified supplementation regimen.\n- Classify the patient’s hepatotoxicity risk category based on the provided modifiers and, using the clinic’s cumulative-dose threshold policy, compute the week at which the noninvasive hepatic fibrosis assessment would be triggered at the current methotrexate dose.\n- Based on the monitoring schedule and the computed trigger week, count the total number of combined CBC-CMP panels that will be obtained from baseline up to and including the last scheduled monitoring time point that occurs before the hepatic assessment is triggered.\n\nProvide as your final answer only the total number of combined CBC-CMP panels to be obtained before the hepatic assessment is triggered. Express your final answer as an integer without units. No rounding instruction is necessary beyond exact counting.", "solution": "The problem is valid as it is scientifically grounded in the principles of clinical pharmacology and dermatology, is well-posed with sufficient and consistent information, and is expressed in objective, formalizable language. The solution requires a sequence of calculations based on the provided clinical scenario and protocols.\n\nThe full solution is derived through the following steps, as requested by the problem statement.\n\nFirst, the weekly methotrexate dose per kilogram of body weight is computed.\nThe patient's weight is given as $W = 70 \\text{ kg}$.\nThe weekly oral methotrexate dose is $D_{weekly} = 15 \\text{ mg}$.\nThe dose per kilogram, $d_{kg}$, is the ratio of the total weekly dose to the patient's weight:\n$$d_{kg} = \\frac{D_{weekly}}{W} = \\frac{15 \\text{ mg}}{70 \\text{ kg}} = \\frac{3}{14} \\frac{\\text{mg}}{\\text{kg}}$$\nThis is approximately $0.214 \\text{ mg/kg}$ per week.\n\nSecond, the total weekly folic acid intake is determined from the supplementation regimen.\nThe protocol specifies folic acid at a dose of $1 \\text{ mg}$ daily, except on the day methotrexate is taken. Since methotrexate is administered once weekly, folic acid is taken on $7 - 1 = 6$ days of the week.\nThe total weekly folic acid intake, $F_{weekly}$, is:\n$$F_{weekly} = 1 \\frac{\\text{mg}}{\\text{day}} \\times 6 \\text{ days} = 6 \\text{ mg}$$\n\nThird, the patient's hepatotoxicity risk is classified, and the time to trigger hepatic fibrosis assessment is calculated.\nThe patient has a body mass index (BMI) of $32 \\text{ kg/m}^2$ (obesity), type $2$ diabetes mellitus, nonalcoholic fatty liver disease (NAFLD), and consumes approximately $14$ standard alcoholic drinks per week. According to the provided criteria, these are features of a high-risk patient.\nFor high-risk patients, the clinic's policy triggers a noninvasive hepatic fibrosis assessment when the cumulative methotrexate dose reaches a threshold of $D_{cumulative\\_threshold} = 1.5 \\text{ g}$.\nWe must convert this threshold to milligrams to match the weekly dosage units:\n$$D_{cumulative\\_threshold} = 1.5 \\text{ g} \\times \\frac{1000 \\text{ mg}}{1 \\text{ g}} = 1500 \\text{ mg}$$\nThe patient receives a stable weekly dose of $D_{weekly} = 15 \\text{ mg}$. The number of weeks, $W_{trigger}$, required to reach the cumulative dose threshold is:\n$$W_{trigger} = \\frac{D_{cumulative\\_threshold}}{D_{weekly}} = \\frac{1500 \\text{ mg}}{15 \\text{ mg/week}} = 100 \\text{ weeks}$$\nThus, the hepatic assessment is triggered at week $100$.\n\nFourth, the total number of combined Complete Blood Count (CBC) and Comprehensive Metabolic Panel (CMP) sets is counted based on the monitoring schedule, up to the trigger week. The assessment is triggered at week $100$, so we must count all scheduled monitoring events at weeks $t < 100$.\n\nThe monitoring schedule is as follows:\n1.  Baseline: A panel is obtained at week $0$. This is $1$ panel.\n2.  Every $2$ weeks through week $12$: Panels are obtained at weeks $2, 4, 6, 8, 10, 12$. The number of panels in this period is $\\frac{12 - 0}{2} = 6$.\n3.  Every $4$ weeks from week $16$ to week $24$: Panels are obtained at weeks $16, 20, 24$. This is $3$ panels.\n4.  Every $8$ weeks thereafter: Panels are obtained at weeks $32, 40, 48, \\dots$. We need to count the number of these time points that are less than week $100$. The series of these weeks can be represented as $t_k = 24 + 8k$ for $k = 1, 2, 3, \\dots$. We find the values of $k$ for which $t_k < 100$:\n    $$24 + 8k < 100$$\n    $$8k < 100 - 24$$\n    $$8k < 76$$\n    $$k < \\frac{76}{8} = 9.5$$\n    Since $k$ must be an integer, the possible values for $k$ are $1, 2, 3, 4, 5, 6, 7, 8, 9$. This corresponds to $9$ monitoring time points (weeks $32, 40, 48, 56, 64, 72, 80, 88, 96$).\n\nThe total number of panels, $N_{panels}$, is the sum of the counts from each interval:\n$$N_{panels} = (\\text{Baseline}) + (\\text{q2wk interval}) + (\\text{q4wk interval}) + (\\text{q8wk interval})$$\n$$N_{panels} = 1 + 6 + 3 + 9 = 19$$\n\nTherefore, a total of $19$ combined CBC-CMP panels will be obtained from baseline up to and including the last scheduled monitoring time point before the hepatic assessment is triggered. The last included monitoring point is at week $96$.", "answer": "$$\\boxed{19}$$", "id": "4488448"}]}